DE60021369T2 - Verfahren zur Abschätzung eines Magengeschwürrisikos - Google Patents
Verfahren zur Abschätzung eines Magengeschwürrisikos Download PDFInfo
- Publication number
- DE60021369T2 DE60021369T2 DE60021369T DE60021369T DE60021369T2 DE 60021369 T2 DE60021369 T2 DE 60021369T2 DE 60021369 T DE60021369 T DE 60021369T DE 60021369 T DE60021369 T DE 60021369T DE 60021369 T2 DE60021369 T2 DE 60021369T2
- Authority
- DE
- Germany
- Prior art keywords
- gastrin
- pepsinogen
- concentration
- gastritis
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 208000007107 Stomach Ulcer Diseases 0.000 title description 8
- 201000005917 gastric ulcer Diseases 0.000 title description 8
- 102400000921 Gastrin Human genes 0.000 claims abstract description 45
- 108010047320 Pepsinogen A Proteins 0.000 claims abstract description 38
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 claims abstract description 38
- 108010066264 gastrin 17 Proteins 0.000 claims abstract description 37
- 210000002966 serum Anatomy 0.000 claims abstract description 35
- 208000008469 Peptic Ulcer Diseases 0.000 claims abstract description 12
- 208000011906 peptic ulcer disease Diseases 0.000 claims abstract description 11
- 241000590002 Helicobacter pylori Species 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 208000025865 Ulcer Diseases 0.000 claims description 7
- 229940037467 helicobacter pylori Drugs 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 231100000397 ulcer Toxicity 0.000 claims description 7
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 5
- 230000000638 stimulation Effects 0.000 claims description 5
- 235000012054 meals Nutrition 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 238000004020 luminiscence type Methods 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 238000002835 absorbance Methods 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 abstract description 44
- 239000012491 analyte Substances 0.000 abstract description 3
- 238000012876 topography Methods 0.000 abstract description 2
- 241000589989 Helicobacter Species 0.000 abstract 1
- 206010003694 Atrophy Diseases 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 108010052343 Gastrins Proteins 0.000 description 12
- 230000037444 atrophy Effects 0.000 description 12
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 12
- 208000023652 chronic gastritis Diseases 0.000 description 12
- 208000004300 Atrophic Gastritis Diseases 0.000 description 7
- 208000036495 Gastritis atrophic Diseases 0.000 description 7
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 208000000718 duodenal ulcer Diseases 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 101800000285 Big gastrin Proteins 0.000 description 5
- 102400000948 Big gastrin Human genes 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- FMIHGWZLPSIAFY-WGFKALLTSA-N gastrin-34 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(N)=O)C(C)C)C1=CC=C(O)C=C1 FMIHGWZLPSIAFY-WGFKALLTSA-N 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 206010019375 Helicobacter infections Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010014475 Pepsinogens Proteins 0.000 description 4
- 102000023022 Pepsinogens Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 108090001072 Gastricsin Proteins 0.000 description 3
- 102000034255 Pepsinogen C Human genes 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000020459 Anaemia of malignant disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 206010054272 Helicobacter gastritis Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 238000008330 Pyloriset EIA-G Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000465 brunner gland Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004691 chief cell of stomach Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- SSBRJDBGIVUNDK-QOGDCIHTSA-N gastrin-14 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 SSBRJDBGIVUNDK-QOGDCIHTSA-N 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010076432 minigastrin Proteins 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/062—Gastritis or peptic ulcer disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Seal Device For Vehicle (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI990992 | 1999-04-30 | ||
| FI990992A FI118653B (fi) | 1999-04-30 | 1999-04-30 | Menetelmä peptisen haavan riskin määrittämiseksi |
| PCT/FI2000/000377 WO2000067035A1 (en) | 1999-04-30 | 2000-04-28 | Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen i (pgi) and gastrin-17 in a serum sample |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60021369D1 DE60021369D1 (de) | 2005-08-25 |
| DE60021369T2 true DE60021369T2 (de) | 2006-05-24 |
Family
ID=8554567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60021369T Expired - Lifetime DE60021369T2 (de) | 1999-04-30 | 2000-04-28 | Verfahren zur Abschätzung eines Magengeschwürrisikos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6872543B1 (https=) |
| EP (1) | EP1173770B1 (https=) |
| JP (1) | JP4598959B2 (https=) |
| CN (1) | CN100573152C (https=) |
| AT (1) | ATE300053T1 (https=) |
| AU (1) | AU4299800A (https=) |
| DE (1) | DE60021369T2 (https=) |
| DK (1) | DK1173770T3 (https=) |
| ES (1) | ES2241597T3 (https=) |
| FI (1) | FI118653B (https=) |
| PT (1) | PT1173770E (https=) |
| RU (1) | RU2225615C2 (https=) |
| WO (1) | WO2000067035A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20010019L (fi) * | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen diagnostisoimiseksi |
| JP2005508838A (ja) * | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | 膵癌の組合せ治療 |
| US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| JP2004536835A (ja) * | 2001-07-09 | 2004-12-09 | アフトン コーポレーション | 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止 |
| SE0200974D0 (sv) * | 2002-03-27 | 2002-03-27 | Phagen Ab | Screening method for gastritis |
| FI119571B (fi) * | 2002-09-06 | 2008-12-31 | Biohit Oyj | Menetelmä esofagiitin tai Barrettin ruokatorven riskin osoittamiseksi yksilöllä |
| JP4689597B2 (ja) * | 2003-03-28 | 2011-05-25 | レセプター バイオロジックス インク． | ガストリンホルモン免疫アッセイ |
| FI119572B (fi) * | 2004-03-05 | 2008-12-31 | Biohit Oyj | Menetelmä vatsan limakalvon tilan ennustamiseksi |
| EP1730193A2 (en) * | 2004-03-29 | 2006-12-13 | Receptor Biologix, Inc. | Monoclonal antibodies to gastrin hormone |
| KR101333168B1 (ko) | 2004-09-22 | 2013-11-28 | 리셉터 바이오로직스 인크 | 프로가스트린에 대한 모노클로날 항체 |
| WO2007007333A2 (en) * | 2005-07-12 | 2007-01-18 | Technion Research And Development Foundation Ltd. | System and method for active detection of asymmetry in rotating structures |
| EP2557425A3 (en) * | 2007-10-26 | 2013-07-10 | Biohit Oyj | Methods and products for diagnosing autoimmune diseases and gastric cancer linked with atrophic gastritis |
| RU2465597C1 (ru) * | 2011-04-08 | 2012-10-27 | Сергей Михайлович Котелевец | Способ определения вероятности развития рака желудка |
| RU2582565C1 (ru) * | 2015-03-06 | 2016-04-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации /ГБОУ ВПО ОрГМУ Минздрава России/ | Способ дифференциальной диагностики язвы желудка и двенадцатиперстной кишки |
| CN104820096B (zh) * | 2015-04-30 | 2017-04-19 | 必欧瀚生物技术（合肥）有限公司 | 一种判断早期胃癌风险检测用标志物的量的联合标准量及在筛查早期胃癌方面的应用 |
| CN107271669A (zh) * | 2016-09-23 | 2017-10-20 | 清华大学深圳研究生院 | 胃蛋白酶原、抗幽门螺杆菌抗体和胃泌素17检测方法及其试剂盒 |
| CN107328938A (zh) * | 2016-09-23 | 2017-11-07 | 清华大学深圳研究生院 | 胃蛋白酶原和抗幽门螺杆菌抗体检测方法及其试剂盒 |
| JP6885581B2 (ja) * | 2017-02-06 | 2021-06-16 | 学校法人東京歯科大学 | ガストリン測定におけるカットオフ値の推定方法 |
| US12150978B2 (en) | 2017-06-15 | 2024-11-26 | Cancer Advances Inc. | Compositions and methods for preventing tumors and cancer |
| WO2018232230A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
| RU2677228C1 (ru) * | 2017-12-08 | 2019-01-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" | Способ иммунодиагностики заболеваний гастродуоденальной зоны |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07304800A (ja) * | 1994-05-06 | 1995-11-21 | Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk | ヒトペプシノゲンに対するモノクローナル抗体 |
| FI97304C (fi) * | 1994-11-16 | 1996-11-25 | Locus Genex Oy | Menetelmä mahasyövän riskin seulonnaksi |
| JP2949474B2 (ja) * | 1995-08-28 | 1999-09-13 | 隆久 古田 | ペプシノーゲンｉ／ｉｉ比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法 |
| JPH10148636A (ja) * | 1996-11-15 | 1998-06-02 | Takahisa Furuta | ペプシノーゲン ｉ／ｉｉ 比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法 |
-
1999
- 1999-04-30 FI FI990992A patent/FI118653B/fi active IP Right Grant
-
2000
- 2000-04-28 US US09/959,551 patent/US6872543B1/en not_active Expired - Lifetime
- 2000-04-28 RU RU2001132335/15A patent/RU2225615C2/ru active
- 2000-04-28 AT AT00922684T patent/ATE300053T1/de not_active IP Right Cessation
- 2000-04-28 JP JP2000615822A patent/JP4598959B2/ja not_active Expired - Lifetime
- 2000-04-28 CN CN00808720.2A patent/CN100573152C/zh not_active Expired - Lifetime
- 2000-04-28 ES ES00922684T patent/ES2241597T3/es not_active Expired - Lifetime
- 2000-04-28 WO PCT/FI2000/000377 patent/WO2000067035A1/en not_active Ceased
- 2000-04-28 EP EP00922684A patent/EP1173770B1/en not_active Expired - Lifetime
- 2000-04-28 PT PT00922684T patent/PT1173770E/pt unknown
- 2000-04-28 DE DE60021369T patent/DE60021369T2/de not_active Expired - Lifetime
- 2000-04-28 DK DK00922684T patent/DK1173770T3/da active
- 2000-04-28 AU AU42998/00A patent/AU4299800A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2225615C2 (ru) | 2004-03-10 |
| FI990992A0 (fi) | 1999-04-30 |
| AU4299800A (en) | 2000-11-17 |
| DE60021369D1 (de) | 2005-08-25 |
| EP1173770A1 (en) | 2002-01-23 |
| FI990992L (fi) | 2000-10-31 |
| ES2241597T3 (es) | 2005-11-01 |
| FI118653B (fi) | 2008-01-31 |
| EP1173770B1 (en) | 2005-07-20 |
| WO2000067035A1 (en) | 2000-11-09 |
| JP4598959B2 (ja) | 2010-12-15 |
| CN100573152C (zh) | 2009-12-23 |
| JP2002543433A (ja) | 2002-12-17 |
| US6872543B1 (en) | 2005-03-29 |
| ATE300053T1 (de) | 2005-08-15 |
| DK1173770T3 (da) | 2005-08-08 |
| CN1355888A (zh) | 2002-06-26 |
| PT1173770E (pt) | 2005-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60021369T2 (de) | Verfahren zur Abschätzung eines Magengeschwürrisikos | |
| DE69525476T2 (de) | Verfahren zum screenen des risikos auf magenkrebs | |
| DE4139840B4 (de) | Antigen-Zubereitung zum Nachweis von H. pylori | |
| DE69735100T2 (de) | Methoden zur diagnose der klinischen subtypen von morbus crohn | |
| WO2004090546A1 (de) | Bestimmung eines midregionalen proadrenomedullin-teilpeptids in biologischen flüssigkeiten zu diagnostischen zwecken sowie immunoassays für die durchführung einer solchen bestimmung | |
| DE69730479T2 (de) | Marker und immunologisches Reagens für Dialyse verbundenen Amyloidosis, Diabetes Mellitus und Diabetes Mellitus-Komplikationen | |
| DE60317070T2 (de) | Verfahren zur diagnose von multipler sklerose | |
| DE69319240T2 (de) | In vitro-test für helicobacter pylori | |
| DE202005020939U1 (de) | Kit zur Messung der Aktivierung neutrophiler Zellen | |
| EP3752838B1 (de) | Methode zur bestimmung der totalen histamin-abbaukapazität in biologischen proben | |
| DE60038614T2 (de) | Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen | |
| Silveira et al. | High levels of IgG4 to Schistosoma mansoni egg antigens in individuals with periportal fibrosis. | |
| CH685959A5 (de) | Diagnostische Testpackung zur Bestimmung von Proteinen. | |
| EP0267355A1 (de) | Verfahren zum Identifizieren gewebstypischer, unlöslicher Cytoskelettproteine | |
| Howitz et al. | Serum-gastrin in vitiligo | |
| DE10101792B4 (de) | Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern | |
| Kubota et al. | Clinicopathologic relationship of hypoganglionosis | |
| DE10006432A1 (de) | Verfahren zum Nachweis von Helicobacter pylori in Stuhl- und Speichelproben | |
| EP1314038B1 (de) | Verfahren zur analyse von stuhlproben für diagnostische zwecke | |
| DE69615537T2 (de) | Helicobacter pylori antigen | |
| DE102009034119A1 (de) | Verfahren, insbesondere Enzyme-linked Immunosorbent Assay (ELISA), zum in vitro Nachweis von Amyloid beta Autoantikörpern, Mikrotiterplatte und Testkit | |
| DE69622799T2 (de) | Abschätzung der Veränderung von Knochen-Mineraldichten und Diagnose von Osteoporose | |
| DE60034525T2 (de) | Bestimmung von Proteinen wie Immunglobuline E (IgE) in Nasensekreten | |
| DE60010872T2 (de) | Verfahren zum nachweis einer prädisposition für venöse thromboembolische erkrankungen | |
| DE602005000636T2 (de) | Verfahren zur Auswertung des Knorpelgewebeabbau |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |